Search clinical trials for: SNDX-5613

Total 74 results

Syndax Pharmaceuticals

Available

Expanded Access Program for SNDX-5613

Relapsed/Refractory Acute Leukemia

United States
M.D. Anderson Cancer Center
Syndax Pharmaceuticals

Not yet recruiting

A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes

Leukemia | HOX Gene

United States
Syndax Pharmaceuticals

Recruiting

Evaluation of SNDX-5613 in Participants With Colorectal Cancer and Other Solid Tumors

Colorectal Cancer | Solid Tumors

United States
Syndax Pharmaceuticals

Recruiting

Study of Radiolabeled SNDX-5613 in Adults With Acute Leukemia

Acute Leukemia

United States
Uma Borate

Recruiting

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia With FLT3/ITD Mutation | Acute Myeloid Leukemia With KMT2A Rearrangement | Acute Myeloid Leukemia With NPM1 Mutation

United States
Syndax Pharmaceuticals

Recruiting

A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

Acute Myeloid Leukemias

United States
M.D. Anderson Cancer Center
AbbVie; Syndax Pharmaceuticals; Break Through Cancer

Not yet recruiting

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

Acute Myeloid Leukemia

United States
Syndax Pharmaceuticals

Active, not recruiting

A Study of SNDX-5613 in Combination With Chemotherapy in Participants With R/R Acute Leukemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Acute Undifferentiated Leukemia | Relapsed/Refractory Leukemias | Mixed Phenotype Acute Leukemia

United States, Canada
Children's Oncology Group

Recruiting

A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | Refractory Mixed Phenotype Acute Leukemia | Refractory Acute Leukemia of Ambiguous Lineage | Recurrent Acute Leukemia of Ambiguous Lineage | Recurrent Acute Myeloid Leukemia... and other conditions

United States
M.D. Anderson Cancer Center
Astex Pharmaceuticals, Inc.; Syndax Pharmaceuticals

Recruiting

A Phase I-II Study Investigating the All Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Acute Myeloid Leukemia

United States
St. Jude Children's Research Hospital
Syndax Pharmaceuticals

Recruiting

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Refractory Acute Myeloid Leukemia | Acute Leukemia of Ambiguous Lineage | Relapsed Acute Myeloid Leukemia

United States
Maximilian Stahl, MD
Syndax Pharmaceuticals

Not yet recruiting

Revumenib in Combination With 7+3 + Midostaurin in AML

Acute Myeloid Leukemia | Leukemia | AML | AML, Adult | AML With Gene Mutations

United States
Syndax Pharmaceuticals

Recruiting

A Study of SNDX-5613 in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Leukemia of Ambiguous Lineage | Mixed Phenotype Acute Leukemia | Mixed Lineage Acute Leukemia

United States, Israel, Spain, Australia, Netherlands, Germany, Canada, France, Italy, Lithuania
Syndax Pharmaceuticals
DevPro Biopharma

Recruiting

Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

Australia
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

Acute Myeloid Leukemia With KMT2A Rearrangement | Acute Myeloid Leukemia With NPM1 Mutation

United States
Syndax Pharmaceuticals

Terminated

A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19

COVID | ARDS | Coronavirus | Cytokine Storm | Cytokine Release Syndrome

United States
University Health Network, Toronto

Recruiting

Thalassemic Iron Overload Cardiomyopathy is Ameliorated by Taurine Supplementation (TICATS)

Thalassemia Major

Canada
Syndax Pharmaceuticals

Active, not recruiting

A Phase 1/2 Study to Evaluate SNDX- 6352 in Participants With Active cGVHD

Chronic Graft-versus-host-disease

United States
Syndax Pharmaceuticals

Active, not recruiting

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) (AGAVE-201)

Chronic Graft-versus-host-disease

Korea, Republic of, United States, Spain, Taiwan, France, Singapore, Belgium, Germany, Italy, Canada, Israel, Australia, United Kingdom, Greece, Poland, Portugal
Syndax Pharmaceuticals

Terminated

A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer

Breast Cancer

United States
National Cancer Institute (NCI)

Withdrawn

Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Pancreatic Carcinoma | Refractory T-Cell Non-Hodgkin Lymphoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC... and other conditions
National Cancer Institute (NCI)

Completed

MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System Neoplasm | Brain Stem Neoplasm | Pineal Region Neoplasm | Recurrent Visual Pathway Glioma | Refractory Visual Pathway Glioma

United States
National Cancer Institute (NCI)

Completed

Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer

Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer

United States
Syndax Pharmaceuticals

Completed

A Phase 1 Study to Investigate SNDX-6352 Alone or in Combination With Durvalumab in Patients With Solid Tumors

Solid Tumor | Unresectable Malignant Neoplasm | Locally Advanced Malignant Neoplasm | Metastatic Tumor

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
AstraZeneca; Syndax Pharmaceuticals

Completed

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

Unresectable Intrahepatic Cholangiocarcinoma

United States
Syndax Pharmaceuticals

Completed

Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC

Carcinoma, Non-Small Cell Lung | Non-Small-Cell Lung Carcinoma

United States
Syndax Pharmaceuticals
Merck Sharp & Dohme LLC

Completed

Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms, Glandular and Epithelial | Digestive System Neoplasms | Endocrine Gland Neoplasms | Breast Diseases | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Bronchial Neoplasms | Solid Tumors | Renal...

United States
Syndax Pharmaceuticals

Terminated

A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma (ENGAGE-501)

Hodgkin's Lymphoma

United States
Syndax Pharmaceuticals

Completed

A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects

Healthy Volunteers | Volunteers | Normal Volunteers | Human Volunteers

United States
Syndax Pharmaceuticals

Completed

A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects

Healthy Volunteer | Drug Interaction

United States
Syndax Pharmaceuticals

Withdrawn

Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer (ENCORE305)

Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Leukemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome

United States
Antonio Fojo

Terminated

Entinostat Neuroendocrine (NE) Tumor

Neuroendocrine Tumors

United States
National Cancer Institute (NCI)

Terminated

Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Unspecified Adult Solid Tumor, Protocol Specific | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic... and other conditions

United States
Syndax Pharmaceuticals
Pfizer; Merck KGaA, Darmstadt, Germany

Completed

Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

United States
Syndax Pharmaceuticals
Roche Pharma AG

Completed

Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In

Breast Cancer

United States, Georgia
Syndax Pharmaceuticals

Terminated

A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib

Non Small Cell Lung Cancer

United States
Syndax Pharmaceuticals

Completed

Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing

ER+ Breast Cancer

Ireland, United Kingdom
Syndax Pharmaceuticals

Completed

Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms, Glandular and Epithelial | Digestive System Neoplasms | Endocrine Gland Neoplasms | Breast Neoplasms | Breast Diseases | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Bronchial Neoplasms | Solid... and other conditions

United States
Syndax Pharmaceuticals

Completed

Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer

Breast Cancer | Estrogen Receptor Positive Breast Cancer

United States
Syndax Pharmaceuticals

Completed

Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer (ENCORE110)

Breast Cancer | Lung Cancer | Non Small Cell Lung Cancer (NSCLC) | Estrogen Receptor Breast Cancer

United States
Syndax Pharmaceuticals

Completed

Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat

Healthy Volunteers | Volunteers | Normal Volunteers | Human Volunteers

United States
Syndax Pharmaceuticals

Completed

A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function

Renal Impairment | Healthy Volunteer

United States
National Cancer Institute (NCI)

Terminated

Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery

Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma

United States
National Cancer Institute (NCI)

Completed

Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Acute Leukemias of Ambiguous Lineage | Untreated Adult Acute Lymphoblastic Leukemia | Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia

United States
National Cancer Institute (NCI)

Completed

Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia... and other conditions

United States
Syndax Pharmaceuticals
Merck Sharp & Dohme LLC

Completed

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer

Melanoma | Non-Small Cell Lung Cancer | Mismatch Repair-Proficient Colorectal Cancer

United States
Jidong Jia
Beijing Ditan Hospital; Huashan Hospital; Ruijin Hospital; Shanghai East Hospital; Tianjin Third Central Hospital and other collaborators

Active, not recruiting

Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF)

Chronic Hepatitis B

China

Search clinical trials for: SNDX-5613

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations